Document:

Exhibit 10.1

FIRST AMENDMENT TO RIGHTS AGREEMENT

This First Amendment (the “Amendment”), dated as of November 10, 2005, between ARI Network Services, Inc., a Wisconsin corporation (the “Company”), and American Stock Transfer & Trust Company (“AST”), to the Rights Agreement between the Company and AST, dated as of August 7, 2003 (the “Rights Agreement”).

WITNESSETH

WHEREAS, the Company and AST previously entered into the Rights Agreement, pursuant to which AST was appointed to serve as the Rights Agent; and

WHEREAS, pursuant to Section 27 of the Rights Agreement, under circumstances set forth therein, (i) the Company may in its sole and absolute discretion supplement or amend any provision of the Rights Agreement without the approval of any holders of Rights or Common Shares, and (ii) upon the delivery of a certificate from an appropriate officer of the Company which states that the proposed supplement or amendment is in compliance with the terms of Section 27 of the Rights Agreement, the Rights Agent shall execute such supplement or amendment; and

WHEREAS, the Company desires to amend the Rights Agreement as set forth herein and to direct AST as Rights Agent to execute this Amendment;

NOW, THEREFORE, in consideration of the promises and the mutual agreements herein set forth, the parties hereby agree as follows:

Section 1.

Direction to Rights Agent.  The Company hereby directs AST, in its capacity as Rights Agent and in accordance with the terms of Section 27 of the Rights Agreement, to execute this Amendment.

Section 2.

Certification of Appropriate Officer.  The undersigned officer of the Company, being duly authorized on behalf of the Company, hereby certifies on behalf of the Company to AST that (a) he is an “appropriate officer” as such term is used in Section 27 of the Rights Agreement, and (b) this Amendment is in compliance with Section 27 of the Rights Agreement.

Section 3.

Amendments of Rights Agreement.  

(a)

Section 1(a) of the Rights Agreement shall be amended to read in its entirety as follows:

“Acquiring Person” shall mean any Person who or which, together with all Affiliates and Associates of such Person, shall be the Beneficial Owner of 10% or more of the Common Shares of the Company then outstanding, but shall not include an Excepted Person so long as such Person continues to meet the definition of Excepted Person, the Company, any Subsidiary of the Company, any employee benefit plan of the Company or of any Subsidiary of the Company, any entity holding Common Shares for or pursuant to the terms of any such plan or any trustee, administrator or fiduciary of such a plan.  Notwithstanding the foregoing, no Person shall become an “Acquiring Person” as the result of an acquisition of Common Shares by the Company which, by reducing the number of shares outstanding, increases the proportionate number of shares beneficially owned by such Person to 10% or more of the Common Shares of the Company then outstanding or, with respect to an Excepted Person, increases the proportionate number of shares beneficially owned by such Person by more than the Excepted Percentage; provided, however, that if a Person shall become the Beneficial Owner of 10% or more of the Common Shares of the Company then outstanding by reason of share purchases by the Company and shall, after such share purchases by the Company, become the Beneficial Owner of an additional 1% or more of the Common Shares of the Company then outstanding, then such Person shall be deemed to be an “Acquiring Person.”  Notwithstanding the foregoing, if the Board determines in good faith that a Person who would otherwise be an “Acquiring Person,” as defined pursuant to the foregoing provisions of this Section 1(a), has become such inadvertently, and without any plan or intention to seek or affect control of the Company, and such Person divests as promptly as practicable (without exercising or retaining any power, including voting, with respect to such shares) a sufficient number of Common Shares so that such Person would no longer be an “Acquiring Person,” as defined pursuant to the foregoing provisions of this Section 1(a), then such Person shall not be deemed to be an “Acquiring Person” for any purposes of this Agreement.

(b)

Section 24(a) of the Rights Agreement shall be amended to read in its entirety as follows:

The Board may, at its option, at any time after any Person becomes an Acquiring Person, exchange all or part of the then outstanding and exercisable Rights (which shall not include Rights that have become null and void pursuant to the provisions of Section 11(a)(ii) hereof) for Common Shares at an exchange ratio of Parity Common Shares per Right (such exchange ratio being hereinafter referred to as the “Exchange Ratio”).

Section 4.

Execution in Counterparts.  This Amendment may be executed in any number of counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute one and the same instrument.

Section 5.

Defined Terms.  Except as otherwise expressly provided herein, or unless the context otherwise requires, all terms used buy not defined herein shall have the meanings assigned to them in the Rights Agreement.

Section 6.

Governing Law.  This Amendment shall be deemed to be a contract made under the laws of the State of Wisconsin and for all purposes shall be governed by and construed in accordance with the laws of such State applicable to contracts to be made and performed entirely within such State.

ARI NETWORK SERVICES, INC.

By:  /s/ Brian E. Dearing                              

Brian E. Dearing, Chairman and

Chief Executive Officer

AMERICAN STOCK TRANSFER &

TRUST COMPANY

By:  /s/ Herbert J. Lemmer                          

Herbert J. Lemmer

Vice Presidentexv10w1

 

AMENDMENT

TO THE

FINISHED PRODUCT SUPPLY AGREEMENT

This Amendment (the “Amendment”) is made and entered into as of August 26, 2005 by and
between Janssen Pharmaceutica, NV, a business corporation organized under the Laws of Belgium,
having its principal office at B-2340 Beerse, Turnhoutseweg 30, Belgium (hereinafter referred to as
“Janssen”) and Barrier Therapeutics, Inc., a Delaware corporation having an address at 600
College Road East, Suite 3200, Princeton, New Jersey 08540 (hereinafter referred to as
“Barrier”).

WHEREAS, Janssen and Barrier are parties to that certain Finished Product Supply Agreement dated
July 14, 2004 (the “Original Agreement”); and

WHEREAS, Janssen and Barrier desire to make certain amendments to the Original Agreement pursuant
to the terms of this Amendment.

NOW, THEREFORE, in consideration of the above premises and the covenants contained herein, the
parties agree as follows:

1. The Original Agreement is hereby amended as follows:

	 	1.1.	 	Section 3.2 of the Original Agreement is hereby deleted and replaced in its
entirety with the following:
	 
	 	 	 	“The Price ex-works for the Finished Product shall be: tube of 60 gram: € 1.00 (one
Euro) per unit.”
	 
	 	1.2.	 	Section 4.1 of the Original Agreement is hereby deleted and replaced in its
entirety with the following:
	 
	 	 	 	“BARRIER commits to purchase a total of 1,000,000 (one million) 60 gram tubes prior
to June 30, 2008.
	 
	 	 	 	In case this Agreement is terminated for whatever reason except breach of contract
by JANSSEN but including without limitation termination under Article 10.3 below,
and BARRIER has not yet purchased and paid a minimum of 1,000,000 (one million) 60
gram tubes on the effective date of termination, BARRIER shall pay to JANSSEN a
penalty equal to of 0.50 Euro (one half Euro) multiplied by the number of 60 gram
tubes that BARRIER has failed to buy and pay compared to the 1,000,000 (one
million) 60 gram tubes minimum.”

 

 

	 	1.3.	 	Section 10.3 of the Original Agreement is hereby deleted and replaced in its
entirety with the following:
	 
	 	 	 	“JANSSEN shall be entitled, but not obligated, to terminate this Agreement at any
time, by way of written notice if, after June 30, 2008, BARRIER has not yet bought
and paid a total of 1,000,000 (1 million) 60 gram tubes of Finished Product”
	 
	 	1.4.	 	The references to “30 gram tubes” in each of Sections 9.1 and on Exhibit I
are hereby amended to read as “60 gram tubes.”
	 
	 	1.5.	 	Section 4.4 of the Original Agreement is hereby deleted and replaced in its
entirety with the following:
	 
	 	 	 	“The following minimum quantities of the Finished Product to be ordered with each
order shall apply: 45,000 (forty-five thousand) 60 gram tubes or a multiple
thereof.”

2. Capitalized terms used herein and not otherwise defined shall have the meanings given to them in
the Original Agreement.

3. Except as expressly amended herein, all terms and conditions of the Original Agreement shall
remain in full force and effect.

4. This Amendment shall in all respects, be subject to substantive Belgian law except that the
Parties explicitly waive the application of the law of July 27, 1961 (as amended).

5. This Amendment may be executed in one or more counterparts, each of which shall for all purposes
be deemed to be an original and all of which shall constitute the same instrument. This Amendment
may be executed by facsimile signature which shall have the same force and effect as the original
signatures.

[ Signatures to Follow ]

2

 

     IN WITNESS WHEREOF, and intending to be legally bound, the parties hereto have caused this
Amendment to be executed by their duly authorized representatives as of the date first set forth
above.

	 	 	 	 	 
	JANSSEN PHARMACEUTICA, NV	 	 
	 
	 	 	 	 
	By:

	 	   RENE HEX
 

	 	 
	Name: Rene Hex	 	 
	Title: CFO & Vice President Finance	 	 
	 
	 	 	 	 
	BARRIER THERAPEUTICS, INC.	 	 
	 
	 	 	 	 
	By:

	 	   AL ALTOMARI
 

	 	 
	Name: Al Altomari	 	 
	Title: Chief Commercial Officer	 	 

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00093-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00093-of-00352.parquet"}]]